Your browser is no longer supported. Please, upgrade your browser.
SNPX [NASD]
Synaptogenix, Inc.
Index- P/E- EPS (ttm)- Insider Own21.00% Shs Outstand3.51M Perf Week-6.44%
Market Cap28.52M Forward P/E- EPS next Y- Insider Trans2.79% Shs Float2.99M Perf Month-12.20%
Income- PEG- EPS next Q- Inst Own12.24% Short Float7.95% Perf Quarter-1.33%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.43 Perf Half Y30.29%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.60 - 14.40 Perf YTD35.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.54% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low212.69% ATR1.33
Employees4 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)42.82 Volatility14.12% 13.83%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.30 Prev Close8.13
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume556.19K Price8.13
Recom- SMA20-14.58% SMA50-10.14% SMA200-2.95% Volume0 Change0.00%
Jul-26-21 09:15AM  
Jul-21-21 09:00AM  
Jul-14-21 09:00AM  
Jul-07-21 09:00AM  
Jun-24-21 09:00AM  
Jun-14-21 09:00AM  
Jun-09-21 09:00AM  
05:38AM  
May-19-21 09:00AM  
May-10-21 09:00AM  
Apr-26-21 09:00AM  
Apr-01-21 09:00AM  
Mar-05-21 09:00AM  
Feb-25-21 09:12AM  
Feb-12-21 09:00AM  
Feb-09-21 09:00AM  
Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Silverman JoshuaDirectorJun 14Buy8.3010,00083,00015,000Jun 16 01:00 PM
Alkon Daniel L.Chief Scientific OfficerJun 14Buy8.2610,00082,60011,484Jun 16 01:01 PM